Pignata S, Cecere SC, Di Maio M. Bevacizumab as first-line treatment of ovarian cancer: strengths and weaknesses of subgroup analyses:  . CBN [Internet]. 2016 Mar. 15 [cited 2024 Nov. 23];4(1):45-7. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/205